
LATEST NEWS
© 2021-2023 Marine Pharmacology
August 2023 ​
-
All links were checked and working properly.
-
Clinical trial numbers were updated accordingly.
o Cytarabine US clinical trials from 434 to 432 and European clinical trials from 127 to 126
o Vidarabine US clinical trials from 23 to 22
o Eribulin Mesylate US clinical trials from 66 to 68
o Brentuximab vedotin US clinical trials from 84 to 82
o Trabectedin US clinical trials from 21 to 20
o Polatuzumab vedotin US clinical trials from 37 to 39
o Disitamab vedotin US clincal trials from 47 to 51 and Chinese clinical trials from 8 to 10
July 2023 ​
-
All links were checked and working properly.
-
Clinical trial numbers were updated accordingly.
o Cytarabine US clinical trials from 440 to 434 and Chinese clinical trials from 53 to 54
o Vidarabine US clinical trials from 24 to 23
o Omega-3-acid ethyl esters US clinical trials from 20 to 18
o Eicosapentaenoic acid ethyl ester US clinical trials from 4 to 7
o Eribulin Mesylate US clinical trials from 33 to 66 and Chinese clinical trials from 9 to 10
o Brentuximab vedotin US clinical trials from 71 to 84
o Trabectedin US clinical trials from 19 to 21
o Polatuzumab vedotin US clinical trials from 25 to 37
o Enfortumab vedotin US clinical trials from 21 to 28, European clinical trials from 10 to 11, and Chinese clinical trials from none to 1
o Lurbinectedin US clinical trials from 23 to 24
o Disitamab vedotin US clincal trials from 32 to 47 and Chinese clinical trials from 7 to 8
June 2023 ​
-
All links were checked and working except the Chinese Clinical Trials links. Chinese clinical trials links were checked for all and updated to:
-
The year-of-FDA-approval link for the Blenrep withdrawal was updated.
-
Panobinostat (Farydak®) and Belantamab Mafodotin-blmf (Blenrep™) were withdrawn​ from accelerated approval and removed from the table.
-
It was noted in the drug table that Omega-3-carboxylic acid (Epanova®) was discontinued in 2021.
-
The Molecular Target was corrected for Panobinostat to deacetylase, Plitidepsin to eEF1A2, Polutuzumab vedotin to CD79b and microtubules, Enfortumab vedotin-ejfv to Nectin-4 and microtubules, Disitimab vedotin to HER2 and microtubules, and Tisotumab vedotin-tftv to TF and microtubules.
-
Clinical trial numbers were updated accordingly.
-
Cytarabine US clinical trials from 428 to 440 and Chinese clinical trials from 48 to 53.
-
Vidarabine US clinical trials from 23 to 24.
-
Omega-3-acid ethyl esters US clinical trials from 22 to 20.
-
Eribulin mesylate US clinical trials from 35 to 33, European clinical trials from 21 to 22, and Chinese clinical trials from 8 to 9.
-
Trabectedin US clinical trials from 20 to 19.
-
Enfortumab vedotin US clinical trials from 19 to 21 and European clinical trials from 9 to 10.
-
Lurbinectedin US clinical trials from 21 to 23.
-
Belantamab mafodotin US clinical trials from 34 to 39 and European clinical trials from 17 to 19.
-
Disitamab vedotin US clinical trials from 29 to 32 and Chinese clinical trials from 6 to 7.
-
Tisotumab vedotin US clinical trials from 3 to 4.
-
April 2023 ​
-
All links were checked and are working properly.
-
​In January we changed Arasena A to the current link, which was not working in early April. At the time of our meeting, it was working again, so we did not to change the link.
-
-
Clinical trial numbers were updated accordingly.
-
Cytaribine US clinical trials from 425 to 428, European clinical trials from 125 to 127, and Chinese clinical trials from 47 to 48
-
Vidarabine US clinical trials from 21 to 23
-
Ziconotide US clinical trials from 1 to 2
-
Omega-3-acid ethyl esters US clinical trials from 24 to 22
-
Eicosapentaenoic acid ethyl ester US clinical trials from 5 to 4
-
Eribulun Mesulate US clinical trials from 36 to 35
-
Brentuximab vedotin US clinical trials from 70 to 69, European clinical trials from 39 to 40
-
Trabectedin US clinical trials from 21 to 20, European clinical trials from 23 to 22
-
Panbinostat US clinical trials from 12 to 11
-
Plitidepsin US clinical trials from 2 to 1
-
Polutuzumab vedotin US clinical trials from 23 to 25
-
Enfortumab vedotin US clinical trials from 18 to 19
-
Lurbinectedin European clinical trials from 4 to 5
-
Disitimab vedotin US clinical trials from 28 to 29
-
March 2023 ​
-
All links were checked and are working properly.
-
Clinical trial numbers were updated accordingly.
-
Cytaribine US clinical trials from 427 to 425
-
Vidarabine US clinical trials from 22 to 21
-
Ziconitide US Clinical trials from 2 to 1
-
Eicosapentaenoic acid ethyl ester European clinical trials from 4 to 2
-
Brentuximab vedotin US clinical trials from 72 to 70, European clinical trials from 39 to 38
-
Polatuzumab vedotin US clinical trials from 22 to 23
-
Lurbinectedin US clinical trials from 20 to 21
-
Belantamab mafodotin US clinical trials from 33 to 34
-
Disitimab vedotin US Clinical trials from 26 to 28 and Chinese clinical trials from 4 to 6
-
February 2023 ​
-
All links were checked and are working properly.
-
​The Omega-3-carboxylic acid (Epanova) trials for Europe were pulling completed studies. I rechecked with looking only for ongoing studies.
-
-
Clinical trial numbers were updated accordingly. ​​​
-
Cytarabine US clinical trials went from 426 to 427, European clinical trials from 126 to 125, and Chinese clinical trials from 46 to 47
-
Omega-3-carboxylic acid trials were updated from 8 to 0, accounting only for ongoing studies
-
Erubilin mesylate Chinese clinical trials were updated from 7 to 8
-
Panbinostat US clinical trials were updated from 13 to 12
-
Plitidepsin US clinical trials were updated from 1 to 2
-
Enfortumab vedotin US clinical trials were udated from 19 to 18
-
Lurbinectedin US clinical trials were updated from 21 to 20
-
January 2023 ​
-
All links were checked and working properly except the Arasena A prescription link. The Arasena A link https://www.nlm.nih.gov/pubs/techbull/ja22/ja22_pubchem.html was updated December 16th, and no longer shows the prescribing information. It has been updated to https://www.gnhindia.com/products/nz-drugs/vira-a-solution-for-infusion-200-mg-ml/.
-
Chinese cliinical trials links are again working.
-
Clinical trial numbers were updated accordingly.
-
Cytarabine US clinical trials from 430 to 426, European clincal trials from 128 to 126, and Chinese clinical trials from 45 to 46​
-
Omega-3-acid ethyl esters US clinical trials from 23 to 24
-
Brentuximab vedotin US clinical trials from 73 to 72 and European clinical trials from 40 to 39
-
Panbinostat US clincal trials from 14 to 13 and European clinical trials from 8 to 7
-
Plitidepsin European clinical trials from 2 to 3
-
Polatuzumab vedotin European clinical trials from 3 to 2
-
Enfortumab vedotin US clinical trials from 18 to 19
-
Lurbinectedin US clinical trials from 17 to 21 and European clincal trials from 3 to 4
-
Disitimab vedotin Chinese clinical trials from 3 to 4
-
December 2022 ​
-
All the links have been checked and were working properly, except links addressing compounds in Chinese clinical trials. We are working with Dr. Jinbo Yang's group to update these links.
-
The approved marine-derived pharmaceutical Belantamab Mafoditin-blmf (Blenrep) withdrawal process was initiated on 11-22-2022, following the request of the FDA. The agency's request was based on the previously announced outcome of the Phase III DREAMM-3 confirmatory trial, which did not meet the requirements of the FDA accelerated approval regulations. (https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-blenrep-us-marketing-authorisation/).
-
Clinical trials numbers were updated accordingly.
-
Cytarabine European clinical trials from 132 to 128​
-
Vidarabine US clinical trials from 48 to 22
-
Omega-3-acid ethyl esters US clinical trials from 24 to 23
-
Erubilin mesylate US clinical trials from 38 to 36
-
Panbinostat US clinical trials from 15 to 14
-
Polutuzumab vedotin US clinical trials from 23 to 22
-
Belantamab mafodotin US clinical trials from 31 to 33 and European clinical trials from 14 to 17
-
Disitimab vedotin US clinical trials from 23 to 26
-
October 2022 ​
-
All the links have been checked and were working properly.
-
The number of current clinical trials was updated accordingly.
-
Cytarabine Chinese clinical trials from 43 to 45​
-
Vidarabine US clinical trials from 49 to 48
-
Erubilin mesylate US clinical trials from 36 to 38
-
Brentuximab vedotin US clinical trials from 74 to 73 and European clinical trials from 42 to 40
-
Trabectedin US clinical trials from 22 to 21
-
Enfortumab vedotin US clinical trials from 17 to 18
-
Lurbinectedin US clinical trials from 18 to 17
-
Belantamab mafodotin US clinical trials from 29 to 31
-
Disitimab vedotin US clinical trials from 20 to 23 and Chinese clinical trials from 1 to 3
-
September 2022
-
Copyright notices were posted on the top and bottom of this page.
-
All the links have been checked and were working properly.
-
The approved marine-derived pharmaceutical Panobinostat (Farydak) was withdrawn on 3-24-2022, and a notice was issued by the Federal Register was added to the webpage (https://www.federalregister.gov/documents/2022/03/24/2022-06182/secura-bio-inc-withdrawal-of-approval-of-new-drug-application-for-farydak-panobinostat-capsules-10).